6LVK image
Entry Detail
PDB ID:
6LVK
Keywords:
TRANSFERASE
Title:
Crystal structure of FGFR2 in complex with 1,3,5-triazine derivative
Biological Source:
Source Organism:
Homo sapiens
Host Organism:
Escherichia coli
PDB Version:
Deposition Date:
2020-02-04
Release Date:
2020-04-08
Method Details:
Experimental Method:
X-RAY DIFFRACTION
Resolution:
2.29 Å
R-Value Free:
0.24
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 2 21 21
6LVK validation report
Macromolecular Entities
Protein Blast
Polymer Type:polypeptide(L)
Description:Fibroblast growth factor receptor 2
Chain IDs:A, B
Chain Length:313
Number of Molecules:2
Biological Source:Homo sapiens
UniProt ID:P21802 Pfam ID:PF07714 EC:2.7.10.1
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
PTR A TYR modified residue
Ligand Molecules
EVC
SO4
Primary Citation
Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2.
Bioorg.Med.Chem. 28 115453 115453 (2020)
PMID: 32278710 DOI: 10.1016/j.bmc.2020.115453

Abstact

Fibroblast growth factor receptor 3 (FGFR3) is an attractive therapeutic target for the treatment of bladder cancer. We identified 1,3,5-triazine derivative 18b and pyrimidine derivative 40a as novel structures with potent and highly selective FGFR3 inhibitory activity over vascular endothelial growth factor receptor 2 (VEGFR2) using a structure-based drug design (SBDD) approach. X-ray crystal structure analysis suggests that interactions between 18b and amino acid residues located in the solvent region (Lys476 and Met488), and between 40a and Met529 located in the back pocket of FGFR3 may underlie the potent FGFR3 inhibitory activity and high kinase selectivity over VEGFR2.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
6LVK